Patient characteristics.
| Variable | N (%) |
|---|---|
| N | 52 |
| Age, median yr (range) | 56 (42–82) |
| Age>60 yr | 24 (46.2) |
| Sex | |
| Male | 30 (57.7) |
| Female | 22 (42.3) |
| ECOG performance status | |
| ≤1 | 46 (88.5) |
| >1 | 6 (11.5) |
| Raised LDH | 16 (30.8) |
| Elevated CSF protein | 7 (13.5) |
| Involvement of deep structuresa) | 34 (65.4) |
| Lymphoma subtype | |
| DLBCL | 52 (100) |
| First-line treatment | |
| MVP | 44 (84.6) |
| R-MVP | 8 (15.4) |
| Response to first-line therapy | |
| CR | 40 (76.9) |
| PR | 8 (15.4) |
| Refractory | 4 (7.7) |
| Auto-SCT | 10 (19.2) |
| Relapse | 26 (50.0) |
| Death | 20 (34.6) |
a)Involvement of deep structures, basal ganglia and/or corpus callosum and/or brain stem and/or cerebellum.
Abbreviations: Auto-SCT, autologous stem cell transplantation; CR, complete response; CSF, cerebrospinal fluid; DLBCL, diffuse large B cell lymphoma; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MVP, methotrexate, vincristine, procarbazine; PR, partial response; R-MVP, rituximab, methotrexate, vincristine, procarbazine.
Blood Res 2020;55:99~106 https://doi.org/10.5045/br.2020.2020032
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd